| 1 |
2024 |
Bruno Basil, Blessing K. Myke-Mbata, Onyinye E. Eze, Augustine U. Akubue. From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome – current insights and future directions, Clinical Diabetes and Endocrinology. 2024; 10: 39.
https://doi.org/10.1186/s40842-024-00187-4 |
| 2 |
2023 |
Amedeo Lonardo, Principles of risk stratification in nonalcoholic fatty liver disease. A narrative review emphasizing non-invasive strategies, Exploration of Digestive Diseases. 2023; 188.
https://doi.org/10.37349/edd.2023.00026 |
| 3 |
2024 |
Amedeo Lonardo, Stefano Ballestri, Gyorgy Baffy, Ralf Weiskirchen. Liver fibrosis as a barometer of systemic health by gauging the risk of extrahepatic disease, Metabolism and Target Organ Damage. 2024; 4:
https://doi.org/10.20517/mtod.2024.42 |
| 4 |
2023 |
Amedeo Lonardo, Iron depletion in “metabolic fatty liver syndromes”: a strong biological rationale with disappointing liver outcomes, Exploration of Drug Science. 2023; 239.
https://doi.org/10.37349/eds.2023.00016 |
| 5 |
2023 |
Amedeo Lonardo, MASLD co-aggregates with HCC in families-names change, fa(c)ts remain, Hepatoma Research. 2023;
https://doi.org/10.20517/2394-5079.2023.110 |
